Literature DB >> 34541682

CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.

Hanyue Ying1, Ruping Zhao2, Qingqing Yu2, Ke Zhang2, Qinghua Deng2.   

Abstract

Circular RNAs (circRNAs) play vital regulatory roles in the development of ovarian cancer (OC). However, the functions of circRNA Atlastin GTPase 2 (circATL2) in paclitaxel (PTX) resistance of OC are still unclear. As a result, circATL2 was upregulated in PTX-resistant OC tissues and cells. CircATL2 knockdown reduced IC50 of PTX, inhibited colony formation ability and promoted cell cycle arrest and apoptosis in PTX-resistant OC cells. Silencing of circATL2 restrained PTX resistance in vivo. Furthermore, miR-506-3p could be targeted by circATL2 and miR-506-3p inhibition reversed the impacts of circATL2 knockdown on PTX resistance and cell progression in PTX-resistant OC cells. NFIB was identified as the target of miR-506-3p. MiR-506-3p overexpression suppressed PTX resistance and malignant behaviors of PTX-resistant OC cells, with NFIB elevation rescued the impacts. To summarize, circATL2 promoted the resistance of OC to PTX by sponging miR-506-3p to upregulate NFIB expression, providing a new sight in chemoresistance of OC.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  NFIB; OC; chemoresistance; circATL2; miR-506-3p; paclitaxel

Mesh:

Substances:

Year:  2021        PMID: 34541682     DOI: 10.1002/ddr.21882

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  2 in total

1.  CircDLG1 promotes malignant development of non-small cell lung cancer through regulation of the miR-630/CENPF axis.

Authors:  Yingying Chen; Ying Zhang
Journal:  Strahlenther Onkol       Date:  2022-06-24       Impact factor: 3.621

Review 2.  Emerging role of circular RNAs in the pathogenesis of ovarian cancer.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Majid Samsami
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.